Last $8.09 USD
Change Today -0.05 / -0.61%
Volume 693.9K
SPPI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

spectrum pharmaceuticals inc (SPPI) Key Developments

Spectrum Pharmaceuticals, Inc. Provides Licenses Rights for Greater China to CASI Pharmaceuticals, Inc. for Three of its Drugs

Spectrum Pharmaceuticals, Inc. and CASI Pharmaceuticals, Inc. announced the signing of license agreements whereby CASI has been granted rights to two of Spectrum Pharmaceuticals commercial oncology drugs, Zevalin(R) (ibritumomab tiuxetan) Injection for intravenous use and Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, and a Phase 3 drug candidate, Captisol-Enabled(TM) Melphalan (CE melphalan), for development and commercialization in China, including Taiwan, Hong Kong and Macau. ZEVALIN is used in the treatment of non-Hodgkin's lymphoma (NHL) and MARQIBO is used in the treatment of acute lymphoblastic leukemia (ALL). CE melphalan has met the endpoints in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum plans to file a New Drug Application with the U.S. Food and Drug Administration (FDA) for CE melphalan in the second half of 2014. CASI will be responsible for the development and commercialization of the three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China, if and as required.

Spectrum Pharmaceuticals Announces Phase 3 Go/No-Go Decision for SPI-2012, Long Acting Granulocyte Stimulating Factor

Spectrum Pharmaceuticals announced the Phase 3 Go/No-Go decision for SPI-2012, its long acting Granulocyte Stimulating Factor (GCSF), and is planning for the start of Phase 3 clinical trials next year. The company's Phase 2 trial was a multicenter, dose-ranging study that evaluated the effectiveness and safety of SPI-2012 relative to a fixed, standard dose of pegfilgrastim as a concurrent active control. The primary objective and endpoint of this study was to assess the effect of SPI-2012 on the mean duration of severe neutropenia during Cycle 1 in patients with breast cancer who received adjuvant or neoadjuvant chemotherapy. Three doses of SPI-2012 were evaluated compared to pegfilgrastim. The company plans to present results for presentation at a premier scientific conference in the first half of 2015.

Spectrum Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 08:35 AM

Spectrum Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 08:35 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Rajesh C. Shrotriya, Chairman, Chief Executive Officer, Chairman of Product Acquisition Committee and Chairman of Placement Committee.

Spectrum Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 11:00 AM

Spectrum Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 11:00 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States.

Spectrum Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Spectrum Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $46,855,000 compared to $33,232,000 a year ago. Loss from operations was $1,396,000 compared to $12,529,000 a year ago. Loss before income taxes was $4,864,000 compared to $12,692,000 a year ago. Net loss was $3,563,000 or $0.06 basic and diluted per share compared to $9,721,000 or $0.16 basic and diluted per share a year ago. Non-GAAP product sales & license and contract revenue was $46,855,000 compared to $33,232,000 a year ago. Non-GAAP income from operations was $8,106,000 compared to non-GAAP loss from operations of $5,159,000 a year ago. The company recorded non-GAAP net income of $6.828 million, or $0.09 per diluted share, compared to a non-GAAP net loss of $5.322 million, or $0.09 per basic and diluted share in the comparable period in 2013. For the six months period, the company reported total revenues of $86,979,000 compared to $71,899,000 a year ago. Loss from operations was $25,810,000 compared to $18,986,000 a year ago. Loss before income taxes was $32,427,000 compared to $20,467,000 a year ago. Net loss was $31,204,000 or $0.49 basic and diluted per share compared to $15,157,000 or $0.26 basic and diluted per share a year ago. Non-GAAP product sales & license and contract revenue was $86,979,000 compared to $65,674,000 a year ago. Non-GAAP income from operations was $10,355,000 compared to non-GAAP loss from operations of $8,849,000 a year ago. The company recorded non-GAAP net income of $7.799 million, or $0.10 per diluted share, compared to a non-GAAP net loss of $10.330 million, or $0.18 per basic and diluted share in the comparable period in 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPI:US $8.09 USD -0.05

SPPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.48 USD -0.09
CTI BioPharma Corp $2.40 USD -0.02
GlaxoSmithKline SAE £14.00 EGP +0.07
Pfizer Ltd/India 1,661 INR -2.25
Wyeth Ltd 1,086 INR -3.95
View Industry Companies
 

Industry Analysis

SPPI

Industry Average

Valuation SPPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRUM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.